



**Somatuline® Depot**  
(lanreotide) Injection 120 mg

Actor portrayals

# MAKE TODAY A TURNING POINT

**ASK YOUR DOCTOR ABOUT SOMATULINE® DEPOT**

**LOOK INSIDE TO FIND OUT HOW SOMATULINE DEPOT TREATS  
GASTROINTESTINAL AND PANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS)  
AND CARCINOID SYNDROME**

## **IMPORTANT SAFETY INFORMATION**

- **Do not take SOMATULINE DEPOT** if you are allergic to lanreotide.
- **SOMATULINE DEPOT may cause serious side effects**, including:
  - Gallstones
  - Fatty stool
  - Changes to your blood sugar (high or low blood sugar),
  - Slow heart rate, and
  - High blood pressure.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



## WHAT ARE GEP-NETs?



GEP-NETs are **gastrointestinal and pancreatic neuroendocrine tumors**. They are a rare type of cancer that can occur in the pancreas and/or gastrointestinal tract.

**It can take a while** for doctors to diagnose GEP-NETs. That's because symptoms can mimic more common diseases and, in the early stages, there may be no symptoms at all.

- Sometimes GEP-NETs are detected during an unrelated scan or surgery for another condition
- Sometimes GEP-NETs aren't diagnosed until the disease has advanced. Tumors can't be completely removed through surgery but can still be treated with certain medications

### What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

## WHAT IS CARCINOID SYNDROME?

Carcinoid syndrome occurs when a neuroendocrine tumor **secretes certain chemicals** into your bloodstream. That causes signs and symptoms such as **diarrhea** and **flushing**.



Flushing is a redness of the skin that suddenly appears on the face, neck, and other parts of the body.





## HOW COMMON ARE NETs?



About **12,000** people each year are diagnosed with **gastrointestinal, pancreatic, neuroendocrine, or carcinoid tumors** in the United States.

### IMPORTANT SAFETY INFORMATION (continued)

- **Tell your healthcare provider (HCP) if you have any of the following symptoms:**
  - **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
  - **Fatty stool** SOMATULINE DEPOT may cause your body to have issues absorbing dietary fats. Tell your healthcare provider if you have any new or worsening symptoms including fatty stools, changes in the color of your stools, loose stools, stomach (abdominal) bloating or weight loss.
  - **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



### **Somatuline® Depot**

(pronounced So-mah-tu-leen Dee-Poh) is

**FDA-approved** treatment for adults to slow the growth of **gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs)** that have spread or cannot be removed by surgery, and treat **carcinoid syndrome** to reduce the need for the use of short-acting somatostatin medicine.

# SLOWS THE GROWTH OF TUMORS

In a clinical study,  
Somatuline<sup>®</sup> Depot

**REDUCED THE RISK OF  
DISEASE PROGRESSION  
OR DEATH BY**

# 53%

versus placebo, in patients  
whose disease had spread or  
could not be removed by surgery.

At 22 months, **more than half** of the patients taking Somatuline Depot lived longer without disease progression. At 16.6 months, half of the patients taking sterile injection placebo had their cancer progress.

## IMPORTANT SAFETY INFORMATION (continued)

- **Tell your healthcare provider (HCP) if you have any of the following symptoms: (continued):**
  - **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
  - **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.

# ABOUT THE STUDY

Somatuline Depot was **studied for nearly 2 years** in adults with GEP-NETs that had spread or could not be removed by surgery. In some patients, the cancer started in their pancreas. In others, it started elsewhere such as in their intestinal tract, which includes the colon. There were **204 patients** in the study. Patients were divided into 2 groups, which received either Somatuline Depot 120 mg or placebo by deep subcutaneous injection every 4 weeks.



Talk to your doctor and see if  
Somatuline Depot is right for you.



It is not known if Somatuline Depot is safe and effective in children.

**Please see Important Safety Information throughout, and  
accompanying full Prescribing Information, including  
Patient Information.**



**Somatuline<sup>®</sup> Depot**  
(lanreotide) Injection 120 mg

# TREATS CARCINOID SYNDROME

Somatuline<sup>®</sup> Depot is FDA-approved to treat adults with carcinoid syndrome to **reduce the need** for the use of short-acting somatostatin rescue therapy.

In a clinical study,  
Somatuline<sup>®</sup> Depot

**REDUCED THE USE  
OF SHORT-ACTING  
RESCUE THERAPY BY**

**15%**

versus placebo.

Short-acting rescue therapy is used to lessen symptoms of carcinoid syndrome, including diarrhea and flushing.

## IMPORTANT SAFETY INFORMATION (continued)

- **The most common side effects of SOMATULINE DEPOT in people with:**
  - **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
  - **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



Talk to your doctor and see if  
Somatuline Depot is right for you.

A conversation on side effects is an important part of talking to your doctor about treatment options.



## HOW DOES IT WORK?

Natural somatostatin helps to control the release of many different types of hormones. This hormone is found naturally in the human body.

Somatuline® Depot contains lanreotide, a synthetic, or **man-made, version of** somatostatin.

It's not known exactly how Somatuline Depot works in the body to:

- Delay the growth of GEP-NETs that have spread or cannot be removed by surgery
- Reduce the need for short-acting somatostatin medicine

### IMPORTANT SAFETY INFORMATION (continued)

SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.

Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



The medicine reservoir is made up of tightly packed, microscopic nanotubes, which allows for the **low injection volume** of Somatuline Depot.



Somatuline Depot is slowly released into the bloodstream, which is why you can receive it **monthly**.



# ONCE-MONTHLY SYRINGE INJECTION

You will receive a Somatuline® Depot deep subcutaneous injection **every 4 weeks** administered by your healthcare provider.

To help the injection process during your visit, the Somatuline Depot syringe has been redesigned with a **sturdy grip and plunger** for the administering healthcare provider.



**Somatuline Depot is a deep subcutaneous injection**

Somatuline Depot is **injected deep under the skin of the upper outer area of your buttock.**

- Your injection site should alternate between your right and left buttock from one injection of Somatuline Depot to the next
- Remind your healthcare provider at your visit which side was previously injected



Visit **SomatulineDepot.com**  
to learn more



## IMPORTANT SAFETY INFORMATION (continued)

- **Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:** have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



**Somatuline® Depot**  
(lanreotide) Injection 120 mg

**Tell your HCP about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE® DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.

**Especially tell your HCP if you take:**

- Insulin or other diabetes medicines,
- A cyclosporine (Gengraf, Neoral, or Sandimmune), or
- Medicines that lower your heart rate, such as beta blockers.
- Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

**Tell your HCP if you have any side effect that bothers you or that does not go away.** These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



It is not known if Somatuline Depot is safe and effective in children.



# IPSEN CARES<sup>®</sup>: A CENTRAL SUPPORT SYSTEM FOR ELIGIBLE PATIENTS

**IPSEN CARES<sup>®</sup>** (Coverage, Access, Reimbursement & Education Support) serves as a central point of contact between patients, caregivers, doctors' offices, insurance companies, and specialty pharmacies.



## Insurance coverage

help with navigating the insurance coverage process to determine out-of-pocket costs for treatment



## Copays

copay assistance is available for eligible\* patients



## Free medication

Patient Assistance Program offers free medication to eligible\* patients



## Deliveries

specialty pharmacy services to coordinate timely medication deliveries

## HOW TO ENROLL

For you to enroll in IPSEN CARES, your doctor must complete the IPSEN CARES Enrollment Form, and you must review and sign the patient authorization section. You can also sign the patient authorization online at [IPSENCARES.com](http://IPSENCARES.com).

## QUESTIONS?

An IPSEN CARES<sup>®</sup> Patient Access Manager is available to help you at **(866) 435-5677**, Monday through Friday, 8 am to 8 pm ET, or visit [www.ipsencares.com](http://www.ipsencares.com).

\*See full PAP eligibility criteria at [ipsencares.com](http://ipsencares.com).

**\*Patient Eligibility & Terms and Conditions:** Patients are not eligible for copay assistance through IPSEN CARES<sup>®</sup> if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, "Government Programs"), or where prohibited by law. Patients must be United States residents (including its territories) and enrolled in IPSEN CARES<sup>®</sup> to receive copay program benefits. Patients residing in Massachusetts and California are not eligible for copay assistance. Patients residing in Rhode Island can only receive assistance with the cost of Ipsen products but not the cost of related medical services (injection). Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year.

An annual calendar year maximum copay benefit applies. Patients may remain enrolled in copay assistance as long as eligibility criteria is met.

Patients or guardians are responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients or guardians may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, Health Reimbursement Account, or otherwise to a government or private payor. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or its copay assistance vendor are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Claim reimbursement requests must be submitted within 180 days of treatment date. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary. Copay assistance cannot be sold, purchased, traded, or counterfeited. Void if reproduced.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



## What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

## IMPORTANT SAFETY INFORMATION

- **Do not take SOMATULINE DEPOT** if you are allergic to lanreotide.
- **SOMATULINE DEPOT may cause serious side effects**, including:
  - **Gallstones**
  - **Fatty stool**
  - **Changes to your blood sugar (high or low blood sugar)**,
  - **Slow heart rate**, and
  - **High blood pressure.**
- **Tell your healthcare provider (HCP) if you have any of the following symptoms:**
  - **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.

- **Fatty stool** SOMATULINE DEPOT may cause your body to have issues absorbing dietary fats. Tell your healthcare provider if you have any new or worsening symptoms including fatty stools, changes in the color of your stools, loose stools, stomach (abdominal) bloating or weight loss.
  - **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.
  - **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
  - **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory
- **The most common side effects of SOMATULINE DEPOT in people with:**
    - **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
    - **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs

SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.

Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



### IMPORTANT SAFETY INFORMATION (continued)

- **Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:** have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.
- **Tell your HCP about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.
- **Especially tell your HCP if you take:**
  - Insulin or other diabetes medicines,
  - A cyclosporine (Gengraf, Neoral, or Sandimmune), or
  - Medicines that lower your heart rate, such as beta blockers.
  - Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

**Tell your HCP if you have any side effect that bothers you or that does not go away.** These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

**To report SUSPECTED ADVERSE REACTIONS,** contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see accompanying full Prescribing Information, including **Patient Information**.



Visit [SomatulineDepot.com](http://SomatulineDepot.com)  
to learn more

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



**Somatuline® Depot**  
(lanreotide) Injection 120 mg

## NOTES



**Somatuline® Depot**  
(lanreotide) Injection 120 mg

## SOMATULINE® DEPOT

**SLOWS THE GROWTH  
OF TUMORS**

**TREATS CARCINOID  
SYNDROME**

### What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.

IPSEN CARES is a registered trademark of Ipsen S.A.

©2024 Ipsen Biopharmaceuticals, Inc. August 2024. SMD-US-004149 v3.0

